Johnson & Johnson (NYSE:JNJ) on Thursday presented detailed results from its Phase 2/3 ENERGY study showing that IMAAVY (nipocalimab-aahu) achieved a statistically significant, durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA).

The rare blood disorder occurs when the immune system mistakenly produces IgG antibodies that attack and destroy healthy red blood cells at normal body temperatures.

Read Also:

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

JNJ Drug Demonstrates Durable Hemoglobin Response

The company said patients receiving the 30 mg/kg dose experienced a rapid onset of effect and were about three times more likely to achieve durable hemoglobin improvements than those receiving a placebo over 24 weeks.

The randomized, placebo-controlled trial ...